<DOC>
	<DOCNO>NCT01121133</DOCNO>
	<brief_summary>This open-label , single multiple center study determine interaction rifampin navitoclax ( ABT-263 ) approximately 12 subject cancer .</brief_summary>
	<brief_title>A Study Assess Effect Rifampin Metabolism Navitoclax</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Inclusion Criteria 18 year age older . Has nonhematologic malignancy ( radiographic , histologic , cytologic confirmation ) , hematologic malignancy ( histologic cytologic confirmation ) either : relapsed refractory standard therapy , fail least one prior therapy know effective therapy exists . In investigator 's opinion , subject 's life expectancy least 90 day . If clinically indicate , ( e.g. , subject age 70 ) subject must document brain imaging ( MRI CT ) negative subdural epidural hematoma within 28 day prior first dose study drug . Exclusion Criteria Subjects brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence CNS disease progression determine CT MRI within 21 day prior first dose study drug . History clinically suspicious cancerrelated central nervous system ( CNS ) disease . Has undergone allogeneic stem cell transplant . Has underlying , predispose condition bleed currently exhibit sign bleed . Has active peptic ulcer disease hemorrhagic esophagitis/gastritis . Has active immune thrombocytopenic purpura history refractory platelet transfusion ( within 1 year prior first dose study drug ) . Significant history cardiovascular disease ( e.g. , MI , thrombotic thromboembolic event last 6 month ) , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease . Female subject pregnant breastfeeding . History active medical condition ( ) affect absorption motility ( e.g. , Crohn 's disease , celiac disease , gastroparesis , short bowel syndrome , etc ) . Subject exhibit evidence clinically significant uncontrolled condition ( ) include , limited : tuberculosis diagnosis fever neutropenia within 1 week prior study drug administration Received anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal ( exception hormone hypothyroidism estrogen replacement therapy [ ERT ] , agonists required suppress serum testosterone level [ e.g. , LHRH , GnRH , etc . ] subject prostate cancer Subject currently receive require anticoagulation therapy ( e.g. , warfarin dose ) drug herbal supplement affect platelet function , exception lowdose heparin use maintain patency catheter . Subject use know inhibitor ( e.g. , ketoconazole ) inducer ( e.g. , rifampin carbamazepine ) cytochrome P450 3A ( CYP3A ) within 1 week prior first dose study . Subject history hypersensitivity rifamycins . In opinion Investigator , subject unsuitable candidate receive ABT263 . History clinically suspicious cancerrelated central nervous system ( CNS ) disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>